Open AccessHyperhomocysteinemia, C-677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene, and chronic arterial hypertension in pregnant women
Author(s) -
В. С. Чулков,
Н. К. Вереина,
С. П. Синицын
Publication year - 2012
Publication title -
kardiovaskulârnaâ terapiâ i profilaktika
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.158
H-Index - 16
eISSN - 2619-0125
pISSN - 1728-8800
DOI - 10.15829/1728-8800-2012-1-41-44
Subject(s) - methylenetetrahydrofolate reductase , medicine , hyperhomocysteinemia , genotyping , homocysteine , genotype , gastroenterology , pregnancy , obstetrics , gynecology , endocrinology , gene , genetics , biology
Aim. To investigate the prevalence of C-677T polymorphism of methylenetetrahydrofolate reductase (MTHFR) gene and hyperhomocysteinemia (HHC) in pregnant women with chronic arterial hypertension (CAH). Material and methods. This prospective cohort study included two groups: Group I – pregnant women with CAH (n=80), and Group II – pregnant women without AH (n=40). In all participants, homocysteine (HC) levels were assessed using immunoenzymatic method, at 9-12 weeks, 22-24 weeks, and 30-32 weeks. Genotyping of the C-677T polymorphism of MTHFR gene was performed using polymerase chain reaction. Results. In pregnant women with CAH, HC levels were higher than in women without AH, throughout the pregnancy. Group I also demonstrated higher prevalence of T allele and T/C genotype. In pregnant women with HHC, relative risk (RR) of pre-eclampsia was 3,5 (95% CI 2,0-5,6), of chronic placental insufficiency - 1,2 (95% CI 0,9-1,6), and of intrauterine growth restriction syndrome - 6,4 (95% CI 3,1-13,3). Conclusion. HCC, as well as its combination with C-677T polymorphism of MTHRF gene, could be regarded as a biomarker of complicated pregnancy in women with CAH.